1	2	3	4	5	6	7	8
Bombay . .	2	..	2	4	..	4	9
Calcutta . .	3	..	3	..	..	..	9
Delhi . . .	2	2	4	2	..	2	6
Gauhati . .	..	1	1	2	..	2	2
Gujarat . .	1	3	4	2	3	5	1
Himachal Pradesh	..	..	..	..	1	1	..
Jammu & Kashmir	1	..	1	..	..	..	1
Karnataka . .	3	..	3	4	..	4	..
Kerala . .	..	..	..	..	..	..	3
Madhya Pradesh .	3	1	4	..	1	1	2
Madras . .	4	..	4	6	..	6	2
Orissa . .	1	..	1	2	1	3	1
Patna . .	3	..	3	5	..	5	5
Punjab & Haryana	6	..	6	7	..	7	3
Rajasthan . .	1	..	1	..	1	1	1
Sikkim . .	1	..	1	1	..	1	..
TOTAL :	47	15	62	41	15	56	59

Production of 16-DPA

613. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) names of the companies which are licensed to produce 16-DPA, 3-4 Diamino Benzophenone, Mebendazole, Terbutaline, Fenbendazole, Metoprolol, Piroxicam, Danazole, Salbutamo Sulphate, Nifedipine, Isoxamine along with licensed/registered capacity of each;

(b) whether it is a fact that the total capacity created for each drug is much more than seventh plan target;

(c) what is the projected demand and what is the licensed/registered capacity of each drug alongwith the total production of all sectors of drug industry during the last two years year-wise of each drug;

(d) whether it is also a fact that these items are being exported;

(e) if so, the quantity exported of each drug during the last two years year-wise;

(f) whether it is also a fact that these drugs are allowed for free imports under OGL; and

(g) if so, what is the justification for this permission and what steps have been taken to save valuable foreign exchange?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) To the extent available, information is given in the enclosed Statement-I. (*See* below)

(b) and (c) Out of the above drug intermediates and bulk drugs, 7th Plan working W Group on Drugs and Pharmaceuticals have estimated the demand for only 3 bulk drugs namely Mebendazole, Terbutaline, and Sulbutamol Sulphate. Since Mebendazole and Salbutamol are delicensed drugs, capacty is no constraint for approvals. Details of production of monitored bulk drugs alongwith its demand projection for the last two years, are given in the enclosed Statement-II. (*See* below).

(d) and (e) The details will be collected and placed on the table of the House.

(f) All the bulk drugs referred to in part (a) of the question except Isoxamine are under OGL.

(g) The import policy for a drug is determined in consideration of general factors, including its domestic demand vis-a-vis. indigenous production, technology, cost of production etc.

Statement-I

Name of the Item/Name of the company	A-C Unit	Capacity Licensed/ registered with DGTD/Registered under de-licensing scheme.
1	2	3
1. **16-*DPA***		
(i) M/s. CIPLA	Tonnes	2.400
(ii) M/s. Synthozyme	„	30 000
2. **3-4** *Diamino Benzophenone*		
(i) M/s. Pefco	„	15.000
(ii) M/s. IDL-Agro-chem.	„	3.400
3. *Mebendazole*		
(i) M/s. Cadila Labs.	„	10.000
(ii) M/s. FDC Pvt. Ltd.	„	10 000
(iii) M/s. Raptakos Brett	„	5.000
(iv) M/s. S.G. Chemicals	„	2.000
(v) M/s. Lyphin Chemical	„	20 000
(vi) M/s. Warner Hindustan	„	6.000
(vii) M/s. Fairdeal	„	10.000
(viii) M/s. Camlin	„	1.000
(ix) M/s. Arandy Labs.	„	12.000
(x) M/s. Venkatraman	„	10.000
(xi) M/s. Swadeshi Chemicals	„	50.000

1	2	3
(xii) M/s. Pefco Foundry Chem.	Tonnes	15.000
(xiii) M/s. S.M. Deshpandey	,,	15.000
(xiv) M/s. K.K. Kela ,,	,,	10.000
(xv) M/s. Sanghi Chemicals	,,	10.000
(xvi) M/s. CIPLA	,,	4.000
4. *Terbutaline Sulphate*		
(i) M/s. S.G. Chemicals	Kgs.	500.00
(ii) M/s. Unichem Labs.	,,	100.00
(iii) M/s. Standard Organics	,,	300.00
(iv) M/s. Astra-IDL	,,	1000.00
(v) M/s. CIPLA	,,	850.00
5. *Fenbendazole*		
(i) M/s. Hoechst India Ltd.	Tonnes	3.500
6. *Metoprolol*		
(i) M/s. CIPLA	Kgs.	3000.00
(ii) M/s. Astra-IDL	,,	8000.00
7. *Piroxicam*		
(i) M/s. CIPLA	Kgs.	1000.00
8. *Danazol*		
(i) M/s. Tamil Nadu Dadha	,,	500.00
(ii) M/s. CIPLA	,,	100.00
9. *Salbutamol Sulphate*		
(i) M/s. Camlin	,,	300.00
(ii) M/s. Jayant Vitamin	,,	5000.00
(iii) M/s. Neuland Labs.	,,	1200.00
(iv) M/s. Pefco	,,	300.00
(v) M/s. Standard Organics	,,	1500.00
(vi) M/s. Fairdeal	,,	360 00
(vii) M/s. S.M. Deshpandey	,,	300.00
(viii) M/s. Smith Stanistreet	,,	300.00
(ix) M/s. Biological E.	,,	300.00
(x) M/s. CIPLA	,,	1150.00
10. *Nifedipine*		
(i) M/s. Unichem Labs.	,,	1500.00

1	2	3
11. *Isoxamine*		
(i) M/s. CIPLA	Tonnes	25.000
(ii) M/s. Dr. Reddy Labs.	,,	50.000

Statement-II

Demand Projection/Production (Tons.)

Name of the drug	1984-85		1985-86	
	Demand	Production	Demand	Production
1. Mebendazole	20.48	43.00*	33.01	
2. Terbutaline	0.37	0.29	0.40	
3. Salbutamol Sulphate	0.60	2.00	0.97	

*This includes demand for Thiabendazole also.

Formulations Based on Ranitidine HCL.

614. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) what were the maximum retail prices fixed for formulations based on Ranitidine HCL an Anti-ulcer drug for different packs and different strengths;

(b) whether it is a fact that certain companies are selling these formulations at much higher prices then approved by Government;

(c) if so, what are the names of those companies alongwith prices at which this medicine is being sold to consumer by them;

(d) whether it is also a fact that drug companies are selling the formulations based on imported bulk drugs after getting them produced from small scale units under their brand names despite the fact that these companies are licensed to produce bullt drug indigenously;

(e) if so, names of those companies alongwith them names of the formulations and their prices; and

(f) what steps have been taken to stop such activities which are against the consumer and country's interest?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI R. K. JAICHANDRA SINGH): (a) A maximum retail prices of Rs. 14.17 was fixed for 10's (150mg. tablets) of Unichem Labs. in January, 1987.

(b) and (c) No such instance has come to the notice of Government. However, the representation of M/s Indian Drugs Manufacturers' Association for treating this formulation under price decontrolled category is under examination.

(d) M/s. Glaxo Lab. (India) who was granted letter of intent for manufacture